Marker Therapeutics Inc (MRKR) Stock Price, Quote & News

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND...

Industry: Biotechnology

Sector: Healthcare

Phone: 713 400 6400

Website: markertherapeutics.com

Address:

2450 Holcombe Blvd, MS: BCM251, Houston, United States

Luzaich1 Feb. 22 at 5:20 PM

$MRKR. I was wondering why Alyeska LP did not report shares this quarter, they had a 13G on 11/14/25 -1.280 m shares Any ideas TIA

1 · Reply

Trak2 Feb. 18 at 5:40 PM

$MRKR let’s hope their is a update on trial

0 · Reply

tradingviewcyp Feb. 18 at 3:22 PM

$MRKR During the conference, Dr. Vera and Marker’s management team will conduct one-on-one meetings with registered investors to discuss the Company’s progress across its Multi-Antigen Recognizing (MAR) T cell platform

0 · Reply

tradingviewcyp Feb. 18 at 3:03 PM

$MRKR 30 minutes, no change. First time for this stock, interesting.

0 · Reply

PortfolioProvenance Feb. 17 at 1:12 PM

$MRKR Pre-revenue biotech; early-stage.

0 · Reply

Trak2 Feb. 16 at 5:31 AM

$MRKR i’m thinking a clinical data read out and partnership announcement, let’s hope🙏🏼🙏🏼

0 · Reply

BCa1 Feb. 14 at 4:20 PM

$MRKR Okay does anyone have any thoughts as to why the annual meeting has moved to May? Please be entertaining or have good ideas based on dates. Will this give them time to present data in the trials. Partner up....

1 · Reply

SinglesOverHomeRun Feb. 12 at 6:14 PM

$MRKR She ran on Baylor's data,held within the trendline against market headwinds all the while looking at Vera with the expression - do something u fcxking loser!

0 · Reply

johnny6nine Feb. 12 at 3:19 PM

$MRKR my shares will be sold above $5. full confidence we will make it there someday, and I’ll wait as long as I have to!

0 · Reply

SinglesOverHomeRun Feb. 11 at 6:45 PM

$MRKR

0 · Reply

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 5, 2026, 7:00 AM EST - 7 weeks ago

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Nov 14, 2025, 7:00 AM EST - 3 months ago

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 5, 2025, 7:30 AM EST - 3 months ago

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Nov 3, 2025, 9:15 AM EST - 4 months ago

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Oct 6, 2025, 7:30 AM EDT - 5 months ago

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Aug 28, 2025, 8:00 AM EDT - 6 months ago

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 12:34 PM EDT - 6 months ago

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Aug 26, 2025, 7:00 AM EDT - 6 months ago

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Jul 30, 2025, 8:00 AM EDT - 7 months ago

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Jun 17, 2025, 8:00 AM EDT - 8 months ago

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

May 20, 2025, 8:00 AM EDT - 9 months ago

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 19, 2025, 8:00 AM EDT - 10 months ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Apr 1, 2025, 8:00 AM EDT - 11 months ago

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Mar 31, 2025, 8:45 AM EDT - 11 months ago

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Feb 25, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Dec 19, 2024, 8:06 AM EST - 1 year ago

Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:05 AM EST - 1 year ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Dec 17, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dec 10, 2024, 8:30 AM EST - 1 year ago

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Nov 26, 2024, 11:00 AM EST - 1 year ago

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Nov 14, 2024, 4:30 PM EST - 1 year ago

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

May 15, 2024, 4:15 PM EDT - 1 year ago

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 8, 2024, 7:00 AM EDT - 2 years ago

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Mar 25, 2024, 5:45 PM EDT - 2 years ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Mar 22, 2024, 12:30 PM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Jan 22, 2024, 7:30 AM EST - 2 years ago

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Jan 8, 2024, 8:24 AM EST - 2 years ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Dec 21, 2023, 11:00 AM EST - 2 years ago

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Nov 9, 2023, 5:00 PM EST - 2 years ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 9:03 AM EDT - 2 years ago

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Aug 14, 2023, 4:30 PM EDT - 2 years ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Jul 10, 2023, 7:00 AM EDT - 2 years ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Jun 26, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

May 31, 2023, 6:30 AM EDT - 2 years ago

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

May 8, 2023, 7:30 AM EDT - 3 years ago

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 1, 2023, 7:30 AM EDT - 3 years ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Mar 22, 2023, 8:10 AM EDT - 3 years ago

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Dec 13, 2022, 7:00 AM EST - 3 years ago

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Aug 11, 2022, 4:22 PM EDT - 3 years ago

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

$Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma$

Aug 4, 2022, 4:37 PM EDT - 3 years ago

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

May 13, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

Luzaich1 Feb. 22 at 5:20 PM

$MRKR. I was wondering why Alyeska LP did not report shares this quarter, they had a 13G on 11/14/25 -1.280 m shares Any ideas TIA

1 · Reply

Trak2 Feb. 18 at 5:40 PM

$MRKR let’s hope their is a update on trial

0 · Reply

tradingviewcyp Feb. 18 at 3:22 PM

0 · Reply

tradingviewcyp Feb. 18 at 3:03 PM

$MRKR 30 minutes, no change. First time for this stock, interesting.

0 · Reply

PortfolioProvenance Feb. 17 at 1:12 PM

$MRKR Pre-revenue biotech; early-stage.

0 · Reply

Trak2 Feb. 16 at 5:31 AM

$MRKR i’m thinking a clinical data read out and partnership announcement, let’s hope🙏🏼🙏🏼

0 · Reply

BCa1 Feb. 14 at 4:20 PM

1 · Reply

SinglesOverHomeRun Feb. 12 at 6:14 PM

$MRKR She ran on Baylor's data,held within the trendline against market headwinds all the while looking at Vera with the expression - do something u fcxking loser!

0 · Reply

johnny6nine Feb. 12 at 3:19 PM

$MRKR my shares will be sold above $5. full confidence we will make it there someday, and I’ll wait as long as I have to!

0 · Reply

SinglesOverHomeRun Feb. 11 at 6:45 PM

$MRKR

0 · Reply

Carny Feb. 11 at 5:54 PM

$MRKR 22% Tuts hold. 17 mil outstanding shares, only 1.5% shorted (~118000 shares) and about 300k shares traded per day. with just that info this looks like accumulation. just the tuts dropping price to scoop up the retail shares being shaken out. I suspect in another month with will see the tuts hold up around 30%.

0 · Reply

Carny Feb. 11 at 5:48 PM

$MRKR just getting the snot kicked out of it day after day for a month.

1 · Reply

SinglesOverHomeRun Feb. 11 at 4:40 PM

$MRKR

0 · Reply

WhereAmIGoing Feb. 11 at 4:16 PM

$MRKR Y’all done see that new price target of 1.50? 😝 if you aren’t planning on being here long term… well, you can sell for a loss

0 · Reply

SinglesOverHomeRun Feb. 11 at 3:12 PM

$MRKR Where is Vera? ICE took him? No wonder he like Fireside chats. Keeping ICE and data away. What a loser! Promises is all he has.

0 · Reply

TitusPullo1964 Feb. 10 at 6:53 PM

$MRKR There was no reason for this extreme decline. The news and perspectives are quite positive. In my opinion, there are good chances of getting in again cheaply. Many values have fallen sharply at the moment. But it doesn't just go in one right. It will rise again and the prospects are good. I am and will remain heavily invested and just wait and see. Good luck choosing your investment

0 · Reply

Drugtrade Feb. 10 at 6:44 PM

$MRKR back in made money twice here lfg

0 · Reply

WhereAmIGoing Feb. 10 at 1:29 AM

$MRKR welcome to MRKR - everyone be nice to the new bag holders -> talking to you Sim Sim 😉 or whatever you call yourself these days

0 · Reply

Selett Feb. 9 at 9:00 PM

$MRKR big level here

0 · Reply

SinglesOverHomeRun Feb. 9 at 8:57 PM

$MRKR holy sheeet! look at that!

0 · Reply

RJ5x2 Feb. 9 at 4:31 PM

$MRKR grabbed some more here on sale

0 · Reply

SinglesOverHomeRun Feb. 9 at 4:29 PM

$MRKR going against tailwind

0 · Reply

Market Cap	24.18M
Revenue (ttm)	6.59M
Net Income (ttm)	-10.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-162.82%
Debt to Equity Ratio	0.00

Volume	86,300
Avg Vol	378,532
Day's Range	N/A - N/A
Shares Out	16.67M
Stochastic %K	57%
Beta	1.44
Analysts	Strong Sell
Price Target	$9.03